AMGN compared with IKT: revenue, margins and what each company keeps, and the suppliers and customers both name

AMGNAmgen Inc

Mkt capRevenueRevenue

IKTInhibikase Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

AMGNAmgen Inc

IKTInhibikase Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

IKT: latest quarter is a loss; flow not drawable.Method ›

AMGNAmgen Inc

478.34▲+3.70%· post 479.26· delayed

Mkt cap$249.4BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

IKTInhibikase Therapeutics, Inc.

1.57▲+5.77%· post 1.57· delayed

After hoursNov 4 '26delayed

Mkt cap$206.5MRevenue$79,569Q3 FY23Revenue—

Compare

After hoursNov 4 '26delayed

AMGNAmgen Inc

IKTInhibikase Therapeutics, Inc.

478.34▲+3.70%post 479.26delayed

Price

1.57▲+5.77%post 1.57delayed

$249.4B

Mkt cap

$206.5M

Q3 FY26$10.4B

Revenue

$79,569Q3 FY23

FY25$36.8B

Revenue

—

AMGN478.34▲+3.70%vsIKT1.57▲+5.77%After hoursNov 4 '26delayed

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

8 more · AMGN chain ›

Shared 0

No disclosed counterparties: IKT.

Only IKT 0

None

Role chip = supplier or customerSource: SEC EDGAR

Price

rebased to 0%

AMGN, solidIKT, dashed